business ftse 
European Pharmaceutical Review
OCTOBER 31, 2022
EcoAct’s 12th annual Corporate Climate Reporting Performance Report revealed the biopharmaceutical sector was above average in achieving emission-related goals, with GSK being FTSE 100’s best performer. Yet half (52 percent) of FTSE 100 companies were found not to have reduced emissions aligned to a 1.5°C C trajectory.
Pharmaceutical Technology
MARCH 15, 2023
The Parker Review committee has announced new targets for improving the ethnic diversity of FTSE 350 senior management teams and large private businesses in the UK, which include pharma companies. For all FTSE 250 boards, the Review also set a similar ‘One by 2024’ target.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
APRIL 1, 2024
Since taking the helm in 2012, Soriot has turned AstraZeneca into the second-largest company on the FTSE 100 index and last year received £16.9 Data Colada — run by two business school professors — issued data manipulation accusations against Gino in 2023. and European peers.
Pharmaceutical Technology
OCTOBER 13, 2022
Commitments including $130 trillion of private capital dedicated towards the net-zero transition were hailed as bold steps in the right direction; governments and businesses were finally rallying to get a handle on pollution. War in Ukraine created bitter headwinds in energy markets, and businesses are being buffeted.
pharmaphorum
AUGUST 27, 2020
The Biotechnology and Biological Sciences Research Council (BBSRC), part of UK Research and Innovation (UKRI), works with universities, research organisations, businesses, charities, and government to develop a supportive ecosystem. As a result, the FTSE 350 Pharmaceuticals & Biotech index hit all-time highs in May.
The Guardian - Pharmaceutical Industry
MARCH 10, 2024
Confronted by the huge salaries on offer in the US, London boardrooms are lobbying to be allowed to make their own bosses even wealthier There was a sharp intake of breath last month when the pharmaceuticals group AstraZeneca cemented chief executive Pascal Soriot’s position as the best-paid FTSE 100 boss with a £17m pay package , up from £15.3m
The Guardian - Pharmaceutical Industry
MARCH 1, 2024
Emma Walmsley’s deal, with a high share bonus payout, makes her one of the highest-paid CEOs in the FTSE 100 The annual pay package of the boss of GlaxoSmithKline, Emma Walmsley, has jumped by 50% to £12.7m, mainly because of a higher share bonus payout reflecting the British drugmaker’s improved performance.
Expert insights. Personalized for you.
77 
Let's personalize your content